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Abstract
This article discusses optimal Bayesian crossover designs for generalized linear models.
Crossover trials with t treatments and p periods, for t <= p, are considered. The designs
proposed in this paper minimize the log determinant of the variance of the estimated treat-
ment effects over all possible allocation of the n subjects to the treatment sequences. It is
assumed that the p observations from each subject are mutually correlated while the ob-
servations from different subjects are uncorrelated. Since main interest is in estimating the
treatment effects, the subject effect is assumed to be nuisance, and generalized estimating
equations are used to estimate the marginal means. To address the issue of parameter de-
pendence a Bayesian approach is employed. Prior distributions are assumed on the model
parameters which are then incorporated into the DA-optimal design criterion by integrat-
ing it over the prior distribution. Three case studies, one with binary outcomes in a 4 × 4
crossover trial, second one based on count data for a 2×2 trial and a third one with Gamma
responses in a 3× 2 crossover trial are used to illustrate the proposed method. The effect of
the choice of prior distributions on the designs is also studied. A general equivalence theorem
is stated to verify the optimality of designs obtained.
Keywords: Bayesian designs; Count data; Efficiency; Gamma response; Generalized estimat-
ing equations; Logistic regression.
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1. Introduction
In this article we introduce Bayesian optimal crossover designs for generalized linear
models (GLMs). Crossover trials with t treatments and p periods, for t ≤ p are considered.
The designs selected minimize the log determinant of the variance-covariance matrix of the
treatment effects, over all possible allocation of the n subjects to the treatment sequences.
Due to the dependence of the variance matrix on the model parameters a Bayesian approach
is proposed.
Crossover designs were originally developed to be used in agricultural sciences (Cochran
(1939)). Later, these repeated measurement designs were found to be useful in many
other fields, such as pharmaceutical and clinical trials, bioequivalence and biological stud-
ies. Optimal crossover designs for normal response have been studied by many reserachers,
namely Hedayat and Afsarinejad (1975, 1978), Cheng and Wu (1980), Laska et al. (1983),
Laska and Meisner (1985), Stufken (1991), Carrire and Reinsel (1993), Kushner (1997, 1998)
and Carriere and Huang (2000). For a detailed review of crossover designs, we would like to
refer to the paper by Bose and Dey (2013) and books by Bose and Dey (2009), Senn (2002)
and Jones and Kenward (2014).
Most of the available literature on optimal crossover designs (as discussed above) mainly
focuses on normal responses. However, in biological studies, very often we find responses
that are non-normal (Layard and Arvesen (1978) and Forster (1992)) and have to be modeled
using a generalized linear model (GLM). While methods for analyzing GLM data arising from
crossover trials are available in Senn (2002) and Jones and Kenward (2014), the question of
designing such studies for GLMs in an optimal manner does not seem to have been much
explored in the statistical literature. Waterhouse et al. (2006) studied optimal 2×2 crossover
trial for binary data in some special cases, like the carryover effect is proportional to the
direct treatment effect and no period effects are considered. Adaptive crossover designs
restricted to two period two treatment binary data useful in clinical trials have also been
investigated by Bandyopadhyay et al. (2009).
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In this article, we study optimal Bayesian crossover designs for GLMs. Three case studies
based on non-normal responses are used to illustrate the proposed methodology. Generalized
estimating equations of Liang and Zeger (1986) are used to estimate the marginal means.
The correlation between observations within subjects are modeled using a “working correla-
tion structure”, which is assumed to be compound symmetric or auto regressive in nature.
Since the main interest is in estimating the treatment effects, the subject effects as taken as
nuisance parameters. As in all GLM designs, the variance of the treatment effect estimator
depends on the model parameters. To address the issue of the parameter dependence and ob-
tain robust designs we propose the Bayesian approach to design selection. Bayesian designs
have been a popular choice whenever the variance-covariance matrix depends on the model
parameters, for some references see (Chaloner and Larntz (1989), Dette and Sperlich (1994),
Woods and Van de Ven (2011) and Mylona et al. (2014) ). In our approach, a prior distri-
bution is assumed on the model parameters, which is then incorporated into an appropriate
objective function (variance of the treatment contrast) by integrating and averaging over the
prior distribution. Similar to our Bayesian design criterion, an average criterion called A-
criterion have been used before for crossover designs for normal responses by (Kempton et al.
(2001), Baily and Kunert (2006), Zheng (2013) and Li et al. (2015)).
2. Case studies
For illustration purpose we consider three case studies based on crossover trials involving
binary, count and Gamma responses.
2.1. A four periods four treatments binary response crossover trial
The first case study presented here is from a trial based on the four-period, four treatment
Williams design. It has been reported in Kenward and Jones (1992). The four treatments
are denoted by A,B,C and D. Eighty subjects are randomly assigned to the four treatment
sequences {ABCD,BDAC,CADB,DCBA}, with about twenty subjects allocated to each
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treatment sequence. The response is a binary outcome taking values 1 and 0 based on patient
relief and no relief, respectively.
The research question which arises from the above case study is why did the experimenter
select the 4 treatment sequences {ABCD,BDAC,CADB,DCBA} forming a Williams de-
sign (Williams (1949)). Is this the best possible selection of treatment sequences? The book
by Bose and Dey (2009), page 40 shows that for normal response crossover models, for the
4 treatment and 4 periods case, Williams design is the optimal design. But can we be sure
that the same design applies to a binary response crossover framework as well? Does the
selected design change if the correlation structure between observations change say, from
equicorrelated to auto regressive structure?
2.2. Two periods two treatments Poisson response crossover trial
This study is based on an example described in Layard and Arvesen (1978). Two drugs,
standard drug A and an innovation drug B, is administered for controlling angina in 20
patients. It is known that the innovative drug B is no worse than the standard drug A. For
a given patient, number of angina attacks on weekly basis is assumed to follow a Poisson
distribution (Layard and Arvesen (1978)). Number of attacks for each patient of consecutive
two weeks are recorded. Treatment sequences considered are {AB, BA} and 10 patients are
assigned to each of the treatment sequences. This is a 2-treatments 2-periods crossover trial.
As in case study I, the question arises why does the experimenter choose the design
{AB,BA}. Is this the best or most efficient design under the repeated measures setup when
responses follow a Poisson distribution?
2.3. Three periods two treatments Gamma response trial
The length of hospital stay is an important measure of the success of hospital activity,
costs incurred by patients and the treatment administered to a patient. However, its empir-
ical distribution is often right skewed and a Gamma distribution with a log link has been
seen to be a good fit (Faddy et al. (2009)). In this case study we consider a crossover trial
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where two treatments are applied over three periods and length of hospital stay, assumed to
having a Gamma distribution, is the primary end point.
As in the earlier two case studies, we investigate the best design for a two treatment
three periods design with a gamma response.
3. The model
We consider experiments where there are t treatments and n subjects, and p repeated
measurements are taken from each subject. The observations from each subject may be cor-
related. The marginal distribution of the response Yij is described by a working generalized
linear model with the following three components (Liang and Zeger (1986)):
1. Yij has a distribution from the exponential family form,
f(yij|φij, ψ) = exp {[yijφij − b(φij) + c(yij)]ψ + d(yij, ψ)} (1)
where φij is a function of the model parameters, b(·), c(·) and d(·) are known functions
and ψ is the dispersion parameter. It can be shown that: E(Yij) = µij =
db(φij )
dφij
and
V ar(Yij) =
d2b(φij )
dφ2ij
/ψ.
2. The linear predictor ηij in a repeated measures setup can be written as (Bose and Dey
(2009)),
ηij = ν + βi + τd(i,j) + γd(i−1,j); i = 1 . . . , p, j = 1, . . . , n, (2)
where ν is the fixed unknown parameter, βi represents the effect of the ith period, τs
is the direct effect due to treatment s and γs is the carryover effect due to treatment
s, s = 1, . . . , t. It is assumed that γd(0,j) = 0.
3. The mean of yij denoted by µij is related to ηij through a link function g, where
g(µij) = ηij and the inverse of g exists.
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3.1. Estimation
Regression coefficients as well as their variances are estimated by the GEE approach of
Liang and Zeger (1986) and Zeger et al. (1988). Due to observations from the same subject
being correlated, a “working correlation” matrix, R(α), is used to describe the dependencies
between repeated observations from a subject. Here α is a vector of length l, which fully
characterizes R(α) (Liang and Zeger (1986)). For cases where R(α) is the true correlation
matrix of Yj = (Y1j, · · · , Ypj)′, the covariance of Yj is
Vj = A
1/2
j R(α)A
1/2
j , (3)
Aj = diag(Var(Y1j), . . . ,Var(Ypj)). If the correlation structure is compound symmetric that
is corr(Yij, Yi′j) = α for all i 6= i′, then l = 1, if the correlation structure is left unspecified
then l = p(p−1)
2
. Also, the asymptotic variance for the GEE estimator θˆ (see Zeger et al.
(1988), equation (3.2)) is
V ar(θˆ) =
[
n∑
j=1
∂µ′j
∂θ
V −1j
∂µj
∂θ
]−1
, (4)
where θ = (ν,β′, τ ′,γ′)′, β′ = (β1, · · ·βp), τ ′ = (τ1, · · · , τt) and γ ′ = (γ1, · · · , γt).
However, if the true correlation structure varies from the “working correlation” structure,
then V ar(θˆ) is given by the sandwich formula (Zeger et al. (1988), equation (3.2))
V ar(θˆ) =
[
n∑
j=1
∂µ′j
∂θ
V −1j
∂µj
∂θ
]−1 [ n∑
j=1
∂µ′j
∂θ
V −1j Cov(Yj)V
−1
j
∂µj
∂θ
][
n∑
j=1
∂µ′j
∂θ
V −1j
∂µj
∂θ
]−1
. (5)
For the crossover model (1), the ith element of
∂µj
∂θ
is
∂µij
∂θ
= x′ij
∂g−1(ηij)
∂ηij
, where x′ij
is the ith row of Xj for i = 1, . . . , p. The design matrix is Xj = [1p Pj Tj Fj], where
Pj = Ip; T = (T
′
1, . . . , T
′
n)
′, where Tj is a p × t matrix with its (i, s)th entry equal to 1 if
subject j receives the direct effect of the treatment s in the ith period and zero otherwise;
F = (F ′1, . . . , F
′
n)
′, where Fj is a p × t matrix with its (i, s)th entry equal to 1 if subject j
receives the carryover effect of the treatment s in the ith period and zero otherwise.
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3.2. Specific case: Bernoulli distribution
If Yij ∼ Bernoulli(µij), then the probability mass function of Yij is:
f(yij|µij) = exp
{
yijlog
µij
1− µij + log(1− µij)
}
Comparing with equation (1), we get φij = log
µij
1−µij
, b(φij) = −log(1 − µij) = log(1 +
exp(φij)), c(yij) = 0, ψ = 1 and d(yij, ψ) = 0. The mean of Yij is E(Yij) = µij =
db(φij)
dφij
=
exp(φij)
1+exp(φij) , and Var(Yij) =
d2b(φij)
dφ2ij
/ψ =
exp(φij)
(1+exp(φij))2 = µij(1− µij).
Considering the logit link function to relate the linear predictor ηij to the mean µij,
g(µij) = log
µij
1−µij
. Thus g−1(ηij) =
eηij
1+eηij , and the ith component of
∂µj
∂θ
is
∂µij
∂θ
= x′ij
∂g−1(ηij )
∂ηij
=
x′ij
eηij
(1+eηij )2 = x
′
ijµij(1−µij). This implies ∂µj∂θ = DjXj, where Dj is the diagonal p×p matrix
with elements µij(1 − µij), i = 1, · · · , p. The matrix Aj defined in equation (3) is same as
Dj in this case. Using equation (4), the asymptotic information matrix is:
n∑
j=1
∂µ′j
∂θ
V −1j
∂µj
∂θ
=
n∑
j=1
X ′jDjA
−1/2
j R
−1(α)A
−1/2
j DjXj
=
n∑
j=1
X ′jA
1/2
j R
−1(α)A
1/2
j Xj.
3.3. Specific case: Poisson distribution
If Yij ∼ Poisson(µij), then the probability mass function of Yij is:
f(yij|µij) = exp {yijlog(µij)− µij − log(yij!)}
Comparing with equation (1), we get φij = log(µij), b(φij) = µij = e
φij , c(yij) =
−log(yij!), ψ = 1 and d(yij, ψ) = 0. The mean of Yij is E(Yij) = µij = eφij and Var(Yij) =
eφij = µij .
Using the log link we obtain, g(µij) = log(µij) = ηij , and the ith component of
∂µj
∂θ
is
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∂µij
∂θ
= x′ij
∂g−1(ηij )
∂ηij
= x′ije
ηij = x′ijµij. This implies
∂µj
∂θ
= DjXj , where Dj is the diagonal
p× p matrix with elements µij, i = 1, · · · , p. The matrix Aj defined in equation (3) is again
same as Dj in this case. The asymptotic information matrix is:
n∑
j=1
∂µ′j
∂θ
V −1j
∂µj
∂θ
=
n∑
j=1
X ′jDjA
−1/2
j R
−1(α)A
−1/2
j DjXj
=
n∑
j=1
X ′jA
1/2
j R
−1(α)A
1/2
j Xj.
3.4. Specific case: Gamma distribution
If Yij ∼ Gamma(κ, λij), where κ > 0 is the shape parameter and λij > 0 is the rate
parameter. Then the probability density function of Yij is:
f(yij|λij, κ) = exp
{[
yij
(
−λij
κ
)
+ log
(
λij
κ
)
+ log(yij)
]
κ+ κlog(κ)− log(yij)− logΓκ
}
Comparing with equation (1), we get φij = −λijκ , b(φij) = −log(λijκ ) = −log(−φij), c(yij) =
log(yij), ψ = κ and d(yij, ψ) = κlog(κ) − log(yij)(Γκ) = ψlog(ψ)− log(yij)(Γψ). The mean
of Yij is E(Yij) = µij = κ/λij and Var(Yij) =
k
λ2ij
=
µ2ij
κ
.
In case of a log link function, g(µij) = log(µij) = ηij . The ith component of
∂µj
∂θ
is
∂µij
∂θ
= x′ij
∂g−1(ηij )
∂ηij
= x′ije
ηij = x′ijµij. This implies
∂µj
∂θ
= DjXj , where Dj is the diagonal
p×p matrix with elements µij, i = 1, · · · , p. The matrix Aj defined in equation (3) is diagonal
p× p matrix with elements µ2ij
κ
, i = 1, · · · , p. The asymptotic information matrix is:
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n∑
j=1
∂µ′j
∂θ
V −1j
∂µj
∂θ
=
n∑
j=1
X ′jDjA
−1/2
j R
−1(α)A
−1/2
j DjXj
=
n∑
j=1
X ′j
{√
κIp
}
R−1(α)
{√
κIp
}
Xj
= κ
n∑
j=1
X ′jR
−1(α)Xj.
In case of a reciprocal link function, g(µij) =
1
ηij
. The ith component of
∂µj
∂θ
is
∂µij
∂θ
=
x′ij
∂g−1(ηij)
∂ηij
= −x′ij
η2ij
= −x′ijµ2ij . This implies ∂µj∂θ = DjXj, whereDj is the diagonal p×pmatrix
with elements −µ2ij , i = 1, · · · , p. The matrix Aj defined in equation (3) is A diagonal p× p
matrix with elements
µ2ij
κ
, i = 1, · · · , p. The asymptotic information matrix can be written
as:
n∑
j=1
∂µ′j
∂θ
V −1j
∂µj
∂θ
=
n∑
j=1
X ′jDjA
−1/2
j R
−1(α)A
−1/2
j DjXj
=
n∑
j=1
X ′j
{−√κD∗j}R−1(α){−√κD∗j}Xj
= κ
n∑
j=1
X ′jD
∗
jR
−1(α)D∗jXj,
where D∗j is the diagonal matrix with diagonal elements µij, i = 1, · · · , p.
Note that the shape parameter κ is a multiplicative constant in the expression of the
information matrices and hence does not affect design selection.
4. Approximate designs
For finding optimal crossover designs for the logistic model we use the approximate theory
as in Laska et al. (1983) and Kushner (1997, 1998). Suppose Ω is the set of treatment
sequences of the form ω = (t1, . . . , tp)
′, ti ∈ {1, . . . , t}, and nω is the number of subjects
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assigned to sequence ω. Then, n =
∑
ω∈Ω nω, nω ≥ 0. A design ζ in approximate theory is
specified by the set {pω, ω ∈ Ω} where pω = nω/n, is the proportion of subjects assigned to
treatment sequence ω.
The matrices Tj and Fj depend only on the treatment sequence ω to which the jth subject
is assigned, so Tj = Tω, Fj = Fω, implying, Xj = Xω. Thus, the variance of θˆ is
V arζ(θˆ) =
[∑
ω∈Ω
npω
∂µ′ω
∂θ
V −1ω
∂µω
∂θ
]−1 [∑
ω∈Ω
npω
∂µ′ω
∂θ
V −1ω Cov(Yω)V
−1
ω
∂µω
∂θ
][∑
ω∈Ω
npω
∂µ′ω
∂θ
V −1ω
∂µω
∂θ
]−1
.
(6)
If the true correlation of Yj is equal to R(α) then we have a much simpler form,
V arζ(θˆ) =
[∑
ω∈Ω
npω
∂µ′ω
∂θ
V −1ω
∂µω
∂θ
]−1
. (7)
4.1. Design criterion
In repeated measures trials when the interest is in only estimating direct treatment effect
contrasts, we may instead work with V ar(τˆ ) given by,
V arζ(τˆ ) = EV arζ(θˆ)E
′, (8)
where E is a t×m matrix given by [0t1, 0tp, It, 0tt] and m is the total number of parameters
in θ. Here by 0p1p2 we mean a p1 × p2 matrix of zeros.
The design minimizing the criterion
Λ(ζ, θ, α) = log Det(V arζ(τˆ )). (9)
is known as the DA-optimal design (Atkinson et al. (2007) , page 137). Since it is a GLM
the variance depends on the model parameters as well as the covariance parameters, and the
design obtained is locally optimal.
To obtain DA-optimal designs robust to uncertainties in the parameters we propose a
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Bayesian approach. This method has been used before for logistic regression by Chaloner and Larntz
(1989), and Dror and Steinberg (2006) and for block designs by Woods and Van de Ven
(2011). For repeated measures models, the design which minimizes
Ψ(B, ζ, α) =
∫
B
Λ(ζ, θ, α) dF (θ), (10)
where B ⊂ Rm is the parameter space of parameter vector θ and F (θ) is a proper prior
distribution for θ, is the DA-optimal Bayesian crossover design (or the average DA-optimal
design of Pettersson (2005)). Note, for all working examples (in Sections 5.1, 5.2 and 5.3)
no prior distributions are assigned to the correlation parameters α, designs are obtained
only for some fixed values chosen for α. However, in Section 7 we investigated the design
performance when there are priors on α.
In our computations we have used both uniform and normal priors for θ. The minimiza-
tion of the objective function in (10) with respect to ζ , requires high-dimensional integral
calculation. Similar to Woods and Van de Ven (2011), Latin Hypercube Sampling (LHS)
has been used for deriving an approximate solution of the above optimization problem.
For evaluating the performance of design ζ with respect to the reference design ζ∗ (DA-
optimal Bayesian design), we use an efficiency criterion defined as:
EffD(ζ, ζ
∗,B, α) = [exp {Ψ(B, ζ∗, α)−Ψ(B, ζ, α)}]1/m , (11)
here m is the number of model parameters. Similar efficiency function has been used before
by Woods et al. (2006).
Working correlation matrix structures such as the compound symmetric (or equi-correlated)
and the AR(1) are investigated. Under the equi-correlated covariance structure, Rj =
(1− α)Ip + αJp, and under the AR(1) assumption, Rj = α|i−i′|, i 6= i′.
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5. Examples
5.1. Example 1: Four periods, four treatments binary response trial
In Case study 1, a four periods four treatments crossover trial described in Kenward and Jones
(1992) is considered. There are eighty subjects allocated to the four treatment sequences,
with about twenty subjects per sequence. Treatments are denoted by A, B, C and D. The
treatment sequences form a Williams design given as follows:


A B C D
B D A C
C A D B
D C B A


The response variable is binary in nature. The data set is available in Table 3 of Kenward and Jones
(1992). For a four periods, four treatments trial, there are 24 possible Latin square designs
(LSDs) with every treatment represented once and only once in each row and in each column
(see Table 5.1 Senn (2002)). A special form of Latin square design is called Williams square
design (WSD) in which every treatment follows every other treatment only once. In the case
of normal responses when t = p and t is even, for reduced models (no carryover effects) LSD
and for full models (carryover effects present) WSDs are variance balanced designs (Lawson
(2014), page 361). However, these designs may not be optimal in general. But under some
subject constraints WSD is universally optimal for even t, n ≤ t(t + 2)/2 and 4 ≤ t ≤ 12
(Bose and Dey (2009), page 40).
Instead of using equation (2) directly as the linear predictor ηij we use a reparametrized
version ,
ηij = ν + β
∗
1P1 + β
∗
2P2 + β
∗
3P3 + τ
∗
1T1 + τ
∗
2T2 + τ
∗
3T3 + γ
∗
1C1 + γ
∗
2C2 + γ
∗
3C3, (12)
where
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P1 P2 P3
Period 1 0 0 0
Period 2 1 0 0
Period 3 0 1 0
Period 4 0 0 1
Ti’s and Ci’s for i = 1, · · · , 4, are similarly defined. Also, β1 = 0, βi = β∗i−1, i = 2, . . . , 4,
τA = 0, τB = τ
∗
1 , τC = τ
∗
2 , τD = τ
∗
3 , γA = 0, γB = γ
∗
1 , γC = γ
∗
2 and γD = γ
∗
3 . Note
that carryover effect in the first period is taken to be zero. It is noted that total number of
parameters reduces to m∗ = m− 3, where m in equation (2) was 13 for a 4× 4 design. The
E matrix defined in equation (8) will be of same form but m is replaced by m∗.
Point estimates and corresponding confidence intervals of the parameters are calculated
using PROC GENMOD procedure in SAS software (SAS Institute Inc. (2003)). Results are
summarized in Table 1 for both reduced and full models. In a reduced model it is assumed
that there are no carryover treatment effects, while in a full model both direct and carryover
treatment effects are assumed to be present. The working correlation structure is taken to
be compound symmetric (CS) in nature, the correlation coefficient is estimated to be 0.215.
13
Table 1: Point estimates and confidence intervals for both reduced and full models under the compound
symmetric correlation structure (Example 1).
Parameter Point estimate [95%Confidence interval]
no carryover effect with carryover effect
ν 1.0980 [0.4232 1.7728] 1.0158 [0.3474 1.6842]
β∗1 -0.3056 [-0.8643 0.2532] -0.5525 [-1.2565 0.1515]
β∗2 -0.2414 [-0.8228 0.3399] -0.4842 [-1.2034 0.2349]
β∗3 0.3817 [-0.2391 1.0026] 0.1234 [-0.6888 0.9356]
τ ∗1 -0.3270 [-0.8660 0.2119] -0.2564 [-0.8075 0.2948]
τ ∗2 -0.0681 [-0.6996 0.5635] 0.0069 [-0.6473 0.6610]
τ ∗3 -0.5322 [-1.1684 0.1041] -0.3736 [-1.0165 0.2693]
γ∗1 - 0.1786 [-0.5965 0.9538]
γ∗2 - 0.2242 [-0.5443 0.9927]
γ∗3 - 0.6620 [-0.1352 1.4591]
For a 4 × 4 crossover trial the number of all possible treatment sequences are 44 = 256.
However, in this example we restrict our design space to only 16 treatment sequences, i.e.,
Ω = {ACDB, BDCA, CBAD, DABC, ADCB, BCDA, CABD, DBAC, AABB, BBAA,
CCDD, DDCC, AAAB, BBBA, CCCD, DDDC}. These sequences are chosen since they
can be used to form LSDs (including WSDs) and also non LSD crossover designs. Note
in the normal response case it has been reported that WSDs under certain constraints are
universally optimal for the 4 treatment and 4 period case. Thus, we felt it was enough to
restrict Ω to these 16 sequences. Also lowering the number of treatment sequences increases
our computational speed. The Bayesian designs found, also satisfy the conditions of the
equivalence theorem given in the appendix.
The following prior distributions are considered for the model parameters, θ, for obtaining
the Bayesian optimal design:
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Prior 1: Cartesian product of 95% confidence intervals of parameters given in Table 1.
Prior 2: Cartesian product of the nonnegative part of 95% confidence intervals of parameters
given in Table 1.
Prior 3 and 4: Independent multivariate normal distribution with mean vector as the point
estimates of the parameters given in Table 1 and (for prior 3) the variance is 0.25, (for
prior 4) the variance is 0.50.
Note prior 2 is asymmetric around 0 and priors 3 and 4 are the normal priors with different
variances. The Bayesian crossover design is obtained by minimizing formula 10, and denoting
it by DB.
The performance ofDB is compared with 24 LSDs including 6 WSDs, and 24 extra period
designs (EPDs) (a design in which first three rows correspond to a LSD and the last row
is same as the previous one (Patterson and Lucas (1959)). We noted that the performance
of each LSD is same among the 18 LSDs under the reduced and full models for both of the
correlation structures and priors used. Same is true for 6 WSDs and 24 EPDs. Thus the
results are based on one LSD, one WSD and one EPD.
5.1.1. Reduced model: No carryover effects
The Bayesian DA-optimal design is obtained under three correlation structures, inde-
pendent (α = 0), compound symmetric (CS) and AR(1). The proportions assigned to each
treatment sequence by DB for varying α are plotted in Figure 1. It is noted (see Fig-
ure 1(A)) that under the independent correlation structure (i.e., α = 0), DB utilizes all
the 16 sequences for priors 1, 3 and 4. In the case of prior 2 and α = 0, the sequences
{BDCA,CBAD,BCDA,DBAC,AAAB,BBBA} are left unused. As α increases for the
CS structure, DB utilizes the sequences forming a LSD (ADCB,BCDA,DABC,CBAD)
with almost 100% weightage and equal proportions to each. Under the AR(1) structure,
DB uses only the first eight sequences (see Figure 1(B)). The efficiencies of the LSD, WSD
and EPD with respect to DB are presented in Figure 2 (A). Note that under CS structure
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both LSD and WSD designs are as good as DB, while EPD has lower efficiency, especially
for priors 1 and 2. Efficiencies of LSD and WSD are constant with respect to α and also
overlap. Under the AR(1) structure (see Figure 2 (B)), WSD is more efficient followed by
LSD, and EPD performs worst. Note that performance of EPD also worsens as α increases.
Efficiency comparisons are not much affected by the choice of the priors in the AR(1) case.
5.1.2. Full model: With carryover effect
It is observed from Figures 1 (C) and (D), for α = 0, under priors 2 and 3, DB utilizes all
sequences except {BBBA}. For α = 0, prior 1: sequences {BBBA,CCDD,DDCC} and
prior 4: {BBBA,CCDD,DDCC,AABB}, are left unused , respectively. Under the CS and
AR(1) structure, DB utilizes the first eight sequences with more than 70% of weight (see
Figure 1 (C) and (D)), and as α increases the first eight sequences get more than 80% weight.
It can be observed from Figure 2 (C) and (D) that WSD is most efficient as compared to
LSD and EPD under all correlation structures. Also contrary to the reduced model, here the
LSD performs worse (with about 85% efficiency) than EPD. Efficiency comparisons are not
much affected by the choice of the priors. Equation (14) in Theorem 1 in the appendix has
been used to confirm the DA-optimality of all Bayesian designs obtained for both reduced
and full models.
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Figure 1: Weights (pω) versus the treatment sequences for different α values using priors 1-4 for the model
parameters in Example 1. Treatment sequences labeled as {a, b, ..., p} correspond to the treatment sequences
given in the design space Ω in Example 1 (Section 5.1). (A): Model with no carry over effect and correlation
structure is CS (B): Model with no carry over effect and correlation structure is AR(1) (C): Model with
carry over effect and correlation structure is CS (D): Model with carry over effect and correlation structure
is AR(1)
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Figure 2: Efficiencies of WSD, LSD and EPD compared with DB using priors 1-4 for the model parameters
in Example 1, (A): Model with no carry over effect and correlation structure is CS (B): Model with no carry
over effect and correlation structure is AR(1) (C): Model with carry over effect and correlation structure is
CS (D): Model with carry over effect and correlation structure is AR(1)
5.2. Example 2: Two periods two treatments Poisson response trial
A crossover trial with two drugs given in two periods for controlling angina in 20 patients
is considered. The count of attacks suffered by the patients is assumed to be a Poisson
random variable. Treatment sequences AB and BA are used in the trial. However, we should
note that this design does not permit the unbiased estimation of the treatment contrast
under carryover effect (Jones and Kenward (2014)), though the estimates and corresponding
18
confidence intervals may still be used to choose the prior distributions.
Reparametrizing the linear predictor ηij for this 2× 2 crossover design as done by Laska
and Meisner (1985),
ηij = ν + β
∗P + τ ∗T + γ∗C.
Here, τ ∗ = (τA − τB)/2, γ∗ = (γA − γB)/2, β1 = 0 and β2 = β∗. The variables P is coded
1 for period 2 and zero otherwise, while T, C = 1 for treatment A and −1 for treatment
B. It is assumed that carryover effect is zero in the first period. For a 2 × 2 cross-over
trial compound symmetric and AR(1) correlation structures are equal. Estimation of the
parameters is again done by using PROC GENMOD in SAS software (SAS Institute Inc.
(2003)). Point estimates and their 95% confidence intervals are listed in Table 2. Estimate
of the correlation coefficient is α = 0.0798.
Table 2: Point estimates and confidence intervals for both reduced and full models for Poisson data in
Example 2.
Parameter Point estimate [95% Confidence interval]
no carryover effect with carryover effect
ν 0.0493 [-0.4457 0.5444] -0.0541 [-1.0405 0.9324]
β∗ -0.0011 [-0.4256 0.4234] 0.0541 [-0.4519 0.5600]
τ ∗ 0.5664 [0.1006 1.0322] 0.6419 [-0.1036 1.3873]
γ∗ - 0.1494 [-0.8566 1.1553]
For a 2 × 2 crossover design, the set of all possible treatment sequences is taken to be
Ω = {AB,BA,AA,BB}. The Bayesian design with the DA-optimal allocation of subjects
to the treatment sequences {AB,BA,AA,BB} is denoted by DB. The performance of DB
is compared to DI = {AB,BA,AA,BB} and DII = {AB,BA}. Both DI and DII assigns
equal allocation to each of their treatment sequences.
Following prior distributions for the model parameters were chosen:
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Prior 1: Cartesian product of 95% confidence intervals of parameters given in Table 2.
Prior 2: Cartesian product of the nonnegative part of 95% confidence intervals of parameters
given in Table 2.
Prior 3 and 4: Independent multivariate normal distribution with mean vector as the point
estimates of the parameters given in Table 2 and (for prior 3) the variance is 0.25, (for
prior 4) the variance is 0.50.
5.2.1. Reduced model: No carryover effects
By observing Figure 3 (A), it is concluded that for α = 0, DB utilizes all sequences, for
all priors. For α > 0, the Bayesian crossover design DB for the reduced model consists of
sequences {AB, BA} with approximately equal weightage to each sequence, thus DII and
DB are very similar under the reduced model. From Figure 3 (C) we see that DII is more
efficient than DI and also the performance of DI worsens as α increases. Choices of the prior
distributions do not effect the results. Also, the results matches with those for the normal
response model for a 2× 2 crossover design (Laska and Meisner (1985)).
5.2.2. Full model: With carryover effects
Introducing crossover effects in the model, however changes the results completely except
for the α = 0 case. The Bayesian crossover design DB for the full model now utilizes the
sequences {AA, AB} and its dual. Proportions assigned to the treatment sequences are
sensitive to the choice of the prior distribution as noted from Figure 3 (B). Figure 3 (D)
shows that the design DI has efficiency values close to 1 and performs better than DII .
Also, DII is affected by increasing α (see Figure 3 (D)). For normal responses in case of a
full model, similar results are noted by (Laska and Meisner (1985)). All designs obtained
for the Poisson response here are verified to be DA-optimal using Theorem 1 given in the
Appendix.
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Figure 3: Weights (pω) assigned to each of the treatment sequences for different α values using priors 1-4
for the model parameters in Example 1 in (A): Model with no carry over effect (B): Model with carry over
effect. Efficiency plots of designs DI and DII in (C): Model with no carry over effect (D): Model with carry
over effect
5.3. Example 3: Three periods two treatment Gamma response trial
We consider a hypothetical gamma response trial with two treatments, A and B applied in
three periods. For the 3×2 crossover design the set of all possible treatment sequences is taken
to be Ω = {AAA,AAB,ABB,ABA,BBA,BAA,BAB,BBB}. The response is length of
hospital stay which is assumed to follow a Gamma distribution. The Bayesian crossover
design DB is determined by searching over Ω. The linear predictor is again reparametrized
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as in Example 2, using τ ∗ = (τA − τB)/2, γ∗ = (γA − γB)/2, β1 = 0, βi = β∗i−1, i = 2, 3, and
T, C = 1 for treatment A and −1 for treatment B,
ηij = ν + β
∗
1P1 + β
∗
2P2 + τ
∗T + γ∗C,
it is assumed that carryover effect is zero in the first period.
The data sets are simulated using the parameter values (ν, β∗1 , β
∗
2 , τ
∗) = (0.50, 0.15, 0.20, 0.25)
for a reduced model and (ν, β∗1 , β
∗
2 , τ
∗, γ∗) = (0.50, 0.20, 0.30, 0.25, 0.15) for a full model. We
have considered the treatment sequences ABB and BAA with the assignment of 10 sub-
jects each to generate the data. Observations are assumed to be independent within the
periods. The link function used is the reciprocal link and the shape parameter κ is fixed at
2.0. Point estimates and corresponding confidence intervals of the parameters are calculated
using PROC GENMOD procedure in SAS software (SAS Institute Inc. (2003)).
Following prior distributions for the model parameters are used to obtain the Bayesian
optimal designs:
Prior 1: Cartesian product of 95% confidence intervals of parameters given in Table 3.
Prior 2: Cartesian product of the nonnegative part of 95% confidence intervals of parameters
given in Table 3.
Prior 3: (ν, β∗1 , β
∗
2 , τ
∗, γ∗) ∈ [−100, 100]×[−100, 100]×[−100, 100]×[−100, 100]×[−100, 100].
Prior 4 and 5: Independent multivariate normal distribution with mean vector as the point
estimates of the parameters given in Table 3 and (for prior 4) the variance is 0.25, (for
prior 5) the variance is 0.50.
For the reciprocal link function, we use the restriction ηij > 0, i = 1, · · · , p, j = 1, · · · , n.
Prior 3 is a new prior considered here. Priors similar to prior 3 were not used in Exam-
ples 1 and 2, since such large values of parameters may have introduced singularity in the
asymptotic variance covariance matrix of the parameter estimates.
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The Bayesian design DB has been compared with the following designs:
Da = ABB,BAA,AAB,BBA with equal allocation to each treatment sequence.
Db = ABB,BAA with equal allocation to each treatment sequence.
Dc = ABA,BAB,ABB,BAA with equal allocation to each treatment sequence.
Table 3: Point estimates and confidence intervals for both reduced and full models for Gamma response in
Example 3.
Parameter Point estimate [95% Confidence interval]
no carryover effect with carryover effect
ν 0.5846 [ 0.3137 0.8556] 0.4653 [ 0.2671 0.6635]
β∗1 0.1842 [ -0.0906 0.4591] 0.1360 [ -0.1814 0.4535]
β∗2 0.2422 [ -0.0873 0.5717] 0.3661 [ 0.0818 0.6503]
τ ∗ 0.2310 [ 0.0446 0.4173] 0.2830 [ -0.0150 0.5810]
γ∗ - 0.1178 [ -0.3020 0.5377]
5.3.1. Reduced model: No carryover effects
For log link function, asymptotic variance covariance matrix of parameter estimates does
not depend on the model parameters, θ, as observed from the information matrix given
in section 3.4 under the log link function. Thus results are similar to those in the normal
response case. Under the CS structure, design {ABB, BAA} with equal proportions is the
optimal design for direct treatment effect. Under AR(1) structure, optimal design utilizes
the sequences ABA and BAB with equal proportions.
For reciprocal link function (see Figure 4 (A)), it is seen that for α = 0, all 8 sequences
are utilized by DB except in the case of prior 3 (sequences BAB,ABB are not used). For
most of the positive α values and priors 1, 2 and 5, for the CS structure DB utilizes the
sequences {BBA,BAB,BAA,ABB}. For priors 3 and 4 the sequence BAA is left unused
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for high α values. Under each prior approximately 40% weightage is given to sequence ABB.
With an increase in α, weights on BBA and BAB also increase however weights on BAA
decrease. We also note that the weights on BAA is sensitive to the prior used. From Figure
5 (A), it is noted that Db is most efficient, this is also true for normal responses.
Under AR(1) structure, DB utilizes the sequences {ABA,BAB} with approximately
45% and 55% weightage, respectively, for each priors. These proportions are not affected by
increasing α values (see Figure 4 (B)). From the efficiency plots (see Figure 5 (B)) design
Dc turns out to be the most efficient as compared to Da and Db.
5.3.2. Full model: With carryover effects
For log link function again the results are similar to those in the normal response case.
Under CS structure, {ABB,BAA} is the optimal design and for AR(1) structure, optimal
design is {ABB,AAB,BAA,BBA} with more than 90% weightage given to the sequence
AAB and its dual.
For reciprocal link function, when α = 0, DB uses all sequences. Under both CS and
AR(1) structures, DB uses the sequences {AAB,BAA,ABB,BAA,ABA} (see Figure 4 (C)
and (D)). It is observed that for smaller values of α, the treatment sequence AAA is included
in the design. In Prior 1, the treatment sequence AAA has approximate 30% weight for α = 0
and weightage decreases as α increases. From the efficiency plots (Figure 5 (C) and (D)),
observe that design Da is the most efficient for CS correlation structures. Under the AR(1)
structure, again Da performs well compared to other designs. Under prior 1 and 2, design
Dc has approximate equal efficiency as Da for α > 0.4. Note that, design Da is the optimal
design for normal responses under AR(1) as noted in Laska and Meisner (1985).
Note again all designs obtained in this section are verified to be optimal using Theorem
1 given in the Appendix.
24
0 0.1 0.2 0.3 0.4 0.5
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
Prior 1
p
ω
α
0 0.1 0.2 0.3 0.4 0.5
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
Prior 2
p
ω
0 0.1 0.2 0.3 0.4 0.5
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
Prior 3
p
ω
0 0.1 0.2 0.3 0.4 0.5
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
Prior 4
p
ω
0 0.1 0.2 0.3 0.4 0.5
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
Prior 5
p
ω
0 0.1 0.2 0.3 0.4 0.5
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
p
ω
α
0 0.1 0.2 0.3 0.4 0.5
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
p
ω
 
 
0 0.1 0.2 0.3 0.4 0.5
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
p
ω
0 0.1 0.2 0.3 0.4 0.5
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
p
ω
0 0.1 0.2 0.3 0.4 0.5
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
p
ω
(A)
(B)
0 0.1 0.2 0.3 0.4 0.5
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
p
ω
α
0 0.1 0.2 0.3 0.4 0.5
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
p
ω
0 0.1 0.2 0.3 0.4 0.5
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
p
ω
0 0.1 0.2 0.3 0.4 0.5
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
p
ω
0 0.1 0.2 0.3 0.4 0.5
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
p
ω
0 0.1 0.2 0.3 0.4 0.5
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
p
ω
α
0 0.1 0.2 0.3 0.4 0.5
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
p
ω
0 0.1 0.2 0.3 0.4 0.5
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
p
ω
0 0.1 0.2 0.3 0.4 0.5
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
p
ω
0 0.1 0.2 0.3 0.4 0.5
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
p
ω
 
 
AAA AAB ABB ABA BBA BAA BAB BBB
(C)
(D)
Figure 4: Weights (pω) assigned to each treatment sequence for different α values using priors 1-5 for the
model parameters in Example 3, (A): Model with no carry over effect and correlation structure is CS (B):
Model with no carry over effect and correlation structure is AR(1) (C): Model with carry over effect and
correlation structure is CS (D): Model with carry over effect and correlation structure is AR(1)
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Figure 5: Efficiencies of designs Da, Db and Dc compared with D
B using priors 1-5 for the model parameters
in Example 3, (A): Model with no carry over effect and correlation structure is CS (B): Model with no carry
over effect and correlation structure is AR(1) (C): Model with carry over effect and correlation structure is
CS (D): Model with carry over effect and correlation structure is AR(1)
6. Sensitivity of designs to the assumed correlation structure
Till now in all our computations we assume that the working correlation (WC) matrix
is equal to the true correlation (TC) matrix as defined in equation (7). In this section
we investigate the effect of misspecifying the correlation on performance of designs. For
illustration, Example 1 is used. There are two cases considered: Case (1): the working
correlation structure is compound symmetric but the true correlation structure is AR(1),
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Case (2): the working correlation structure is AR(1) but the true correlation structure
is compound symmetric. Prior 1 used before in Example 1 is assigned to the regression
parameters.
First we consider a model without the carryover effect. The Bayesian DA-optimal design,
DB, is found using equation (6) in equation (10). DB utilizes the sequences forming a LSD
under both cases 1 and 2. Under misspecification, performance of WSD is affected very
slightly (see Figure 6 (A1) and (A2)), EPD performs the worst and its performance worsens
with α.. However, for the TC=WC case, we had noted earlier that both LSD and WSD are
equally efficient. Thus, misspecification under the reduced model case, has a slight adverse
effect on the performance of the WSD but not the LSD.
For the model with carryover effect, for both cases 1 and 2, DB utilizes the first 8
sequences with more than 70% weights (this is consistent with results obtained under TC =
WC). Though the performance of WSD is affected it is still the most efficient compared to
EPD and LSD (see Figure 6 (B1) and (B2)), while LSD is the worst.
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Figure 6: Efficiency plots of WSD, LSD and EPD compared to DB when true correlation (TC) and working
correlation (WC) are not equal (A1) Model without carryover effect and WC = compound symmetric (CS),
TC = autoregressive (AR(1)), (A2) Model without carryover effect and WC = AR(1), TC = CS, (B1)
Model with carryover effect and WC = CS, TC = AR(1), (B2) Model without carryover effect and WC =
AR(1), TC = CS
27
7. Prior distributions on α and its effect on design performances
Designs obtained so far are based on some fixed values of α. In this section, we validate the
performance of the optimal designs using priors on α. For illustration purpose, we consider
the two periods two treatments Poisson response model with carry over effect from Example
2. Prior 1 of Example 2 is chosen for the parameters involved in the linear predictor. The
estimate of α using the data given in Example 2 is 0.0798. Based on this information we use
the following set of priors covering the value 0.0789.
• (i) Uniform(0, 0.2) (ii) Uniform(0, 0.5) (iii) Uniform(0, 0.8) (iv) Uniform(0, 1)
• (i) Beta(2, 38) (ii) Beta(4, 12) (iii) Beta(6, 10) (iv) Beta(5, 5).
The first four uniform and beta priors (i-iv) are chosen such that they have similar ranges,
i.e., the range of uniform (i) is similar to beta prior (i) and so on. They are also chosen to
look at the effect of increasing uncertainty of the prior information on the designs. Uniform
and Beta priors have been used before by Spiegelhalter (2001) and Singh and Mukhopadhyay
(2016) for the correlation parameter of cluster randomized trials.
The DA-optimal Bayesian criterion defined in equation (10) changes to the design which
minimizes
Ψ(B∗, ζ) =
∫
B∗
Λ(ζ, θ, α) dF (θ, α), (13)
where B∗ ⊂ Rm × [0, 1] is the parameter space of parameter vector (θ, α) and F (θ, α) is a
proper prior distribution for (θ, α). Optimal proportions of DB using the above criterion
for different priors of α are given in Table 4. As noted before in Example 2, design DI =
{AA,AB,BA,BB} with equal proportions performs well as compared to the Bayesian DA-
optimal design with efficiency values approximately equal to 1. From Table 4, it is observed
that optimal proportions are slightly sensitive to the choice of priors. For example see the
optimal allocations corresponding to Uniform(0, 0.2) and Beta(5, 5) priors. Overall, we may
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conclude that there is not much change in the results when we use a prior for α instead of
some fixed values.
Table 4: Optimal allocation of DB under different priors for α and efficiency values of DI (Section 7).
pω
Prior AA AB BA BB Efficiency
Uni(0, 0.2) 0.1520 0.2700 0.2133 0.3647 0.988
Uni(0, 0.5) 0.1506 0.2716 0.2161 0.3617 0.988
Uni(0, 0.8) 0.1503 0.2744 0.2167 0.3586 0.988
Uni(0, 1.0) 0.1515 0.2766 0.2124 0.3595 0.988
Beta(2, 38) 0.2000 0.2000 0.3000 0.3000 0.996
Beta(4, 12) 0.1997 0.1992 0.3005 0.3006 0.995
Beta(6, 10) 0.2060 0.1986 0.2908 0.3047 0.991
Beta(5, 5) 0.1843 0.1841 0.2876 0.3440 0.989
8. Computer programs used to obtain the optimal designs and estimate the
parameters
Approximation of the multidimensional integrals of the objective functions in equa-
tions (10) and (13) to obtain the optimal designs is done with Latin Hypercube Sampling
(LHS). For uniform priors, we use the average of (10) and (13) across 100-point discrete
samples using LHS as the approximate solution of (10) and (13), respectively. When θ
has a Gaussian distribution, Latin Hypercube Sampling from Gaussian fields is used (for
more details see Stein (1987)). A MATLAB function lhsdesign is used to sample points
from the parameter space. To obtain the optimal proportions of subjects (pω) assigned
to treatment (ω), fmincon function in MATLAB is used. The fmincon algorithm finds
a minimum of a constrained nonlinear multivariable function, and by default is based on
the Sequential Quadratic Programming algorithm. For more details please see the link
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http://in.mathworks.com/help/optim/ug/fmincon.html#description. A genetic algorithm
(GA function in MATLAB) verifies the results obtained from the fmincon. The estima-
tion and the estimated confidence intervals of model parameters are done using GENMOD
procedure in SAS (SAS Institute Inc. (2003)).
Note: All MATLAB and SAS programs are available to the readers upon request from
the first author of this article.
9. Concluding Remarks
Crossover designs are popular as designs of choice in many clinical and pharmaceutical
trials for comparing treatments. However, very often in these situations the response does
not follow the usual assumptions of normality, and generalized linear models have to be used
to model the data. In this article, we address the designing of such crossover trials when a
GLM is fitted. Since the designs are dependent on the model parameters, Bayesian designs
are proposed. Comparing our main results based on GLMs with those of normal response
models, we see that they are quite similar in many cases.
The main results on the estimation of direct treatment effects using the proposed DA-
optimal Bayesian designs (DB) are summarized below.
• For t = p = 4 when the response is binary : Williams design is as efficient as DB
and is seen to perform the best under both CS and AR(1) correlation structures for a
reduced as well as a full model.
• For p = t = 2 when the response is Poisson distributed: Design {AB,BA}
has the highest efficiency in a reduced model framework while for a full model, design
{AB,BA,AA,BB} is most efficient. Both designs have equivalent efficiency as DB for
the respective models.
• For p = 3, t = 2 when the response is Gamma distributed: Under log link
function, DA-optimal Bayesian designs are same as in case of normal responses.
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For reciprocal link function, under reduced model, design Db (treatment sequences
{ABB, BAA} with equal proportions), perform as well as DB under the CS correla-
tion structure, while for AR(1) correlation structure, design Dc (treatment sequences
{ABA,BAB, ABB,BAA} with equal proportions) has the equal efficiency as DB.
In case of full model, design Da (treatment sequences {ABB,BAA,AAB,BBA} with
equal proportions) is equally efficient as DB, and performs better than Db and Dc.
In many biological experiments while studying the effect of drugs, the response measured
may not be binary in nature but say ordinal. As an example consider a 3× 3 crossover trial
(cited by Jones and Kenward (2014)) where the effect of three treatments on the amount of
patient relief is studied. The response obtained is categorized as none, moderate or complete,
making it ordinal in nature with three categories. Thus, there is a need to address optimal
crossover deigns not just for binary models but also for multi categorical responses. In these
cases, instead of the logit link, a generalized logit or a proportional odds model may be used.
Also, other than the correlation between measurements from the same subject we would have
to consider the relation between response categories. Jones and Kenward (2014) discusses
modeling of ordinal data using the GEE approach. In future, we are interested to study
D-optimal Bayesian designs for such multicategorical models.
Appendix
Consider a finitely supported approximate crossover design with k treatment sequences.
The design can be expressed in the form of a probability measure as follows:
ζ =


ω1 ω2 . . . ωk
pω1 pω2 . . . pωk

 ,
where ωi ∈ Ω (set of all treatment sequences considered) and pωi is the proportion of subjects
assign to treatment sequence ωi such that pωi ≥ 0 and
∑k
i=1 pωi = 1, for i = 1, · · · , k. Let
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M = M(ζ, θ) denotes the asymptotic information matrix of estimates of the parameter
vector θ. This in turn is the reciprocal of the variance-covariance matrix defined in equation
(7). If the interest is in the estimation of a linear combination of the parameters of the form
λ = W ′θ, where W is a m× s matrix with rank s ≤ m. The information matrix of λ for a
design ζ is given by C = C(ζ, λ) = (W ′M−1W )−1. Next theorem insures the optimality of
designs obtain for the estimation of λ under the prior distribution of θ.
Theorem 1. Under the GEE model considered for the linear predictor, link function and
working correlation, the following conditions for a continuous design ζ∗ are equivalent:
1. ζ∗ minimizes Ψ(B, ζ, α) defined in equation (10), ∀ ζ ∈ χ, where χ is the set of all
possible designs.
2. ζ∗ satisfies the following condition:
EF
[
tr
(
M(ζ∗, θ)−1WCW ′M(ζ∗, θ)−1
)
M(ζω, θ)
] ≤ s ∀ ω ∈ Ω, (14)
where F is the prior distribution of θ and M(ζω, θ) is the information matrix with
respect to the design ζω having unit mass at single treatment sequence ω. Equality in
equation (14) is achieved if any ω in the Bayesian DA-optimal design is inserted.
Proof of this theorem follows directly from Theorem 3.1 of Pettersson (2005). These
optimal designs are known as average DA-optimal designs. A similar equivalence theorem is
proved and used by Woods and Van de Ven (2011) to show the optimality of blocked designs
with non-normal responses. Expressions of matrix W , θ and respective ranks for examples
used in this article are:
• Example 1
W ′ =


0 0 0 0 1 0 0 0 0 0
0 0 0 0 0 1 0 0 0 0
0 0 0 0 0 0 1 0 0 0


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θ = (ν, β∗1 , β
∗
2 , β
∗
3 , τ
∗
1 , τ
∗
2 , τ
∗
3 , γ
∗
1 , γ
∗
2 , γ
∗
3)
′ and s = 3.
• Example 2
W ′ =
[
0 0 1 0
]
θ = (ν, β∗, τ ∗, γ∗)′ and s = 1.
• Example 3
W ′ =
[
0 0 0 1 0
]
θ = (ν, β∗1 , β
∗
2 , τ
∗, γ∗)′ and s = 1.
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